Nanalysis Scientific Corp. Announces Grant of Stock Options

Rhea-AI Summary

Nanalysis Scientific Corp. (NSCIF) has granted 377,500 stock options to employees, including 175,000 to an officer, at $1.10 per share, with a five-year exercise period. The options will vest over three years. This move aims to incentivize employees and align their interests with shareholders. Nanalysis specializes in portable Nuclear Magnetic Resonance (NMR) technology for various industries and has an innovation pipeline that includes a new 100MHz device. The company also broadens its market presence through its recent acquisition of K'Prime and a 43% stake in Quad Systems AG.

Positive

• Granting of 377,500 stock options aligns employees' interests with shareholders.
• Nanalysis continues to innovate with a new 100MHz NMR device, enhancing its product offering.
• Strategic acquisition of K'Prime strengthens the company's sales and service capabilities in North America.

Negative

• None.

CALGARY, AB, Aug. 30, 2022 /PRNewswire/ - Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1) ("Nanalysis" or the "Company") announces that the Company's Board of Directors has granted a total of 377,500 stock options to its employees, including 175,000 to an officer, pursuant to the Company's stock option plan. Each option is exercisable to purchase one common share in the capital of the Company at $1.10 per share for a period of five years from the date of issuance. The options vest as to one-third on each of the 12 month, 24 month and 36 month anniversary date of grant. 

About Nanalysis Scientific Corp. (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1)

Nanalysis trades on the TSX Venture Exchange (TSXV) in Canada with ticker symbol 'NSCI', OTC and the Frankfurt exchange under the ticker symbol '1N1'. The company's business is what we term "MRI and NMR for industry". The company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. Nanalysis recently announced that it has begun selling a 100MHz device in 2020. The Company's new device will be the most powerful and most advanced compact NMR device ever brought to market.

Nanalysis devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.

With the recent acquisition of K'Prime, the company maintains a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.

Additionally, the Company has a 43% ownership in Quad Systems AG ("Quad Systems"), with an option to purchase the remaining shares. Quad Systems is a Zurich-based Nuclear Magnetic Resonance (NMR) company focused on high-field NMR for pharmaceutical and other vertical markets.

Notice regarding Forward Looking Statements and Legal Disclaimer

This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanalysis-scientific-corp-announces-grant-of-stock-options-301615057.html

SOURCE Nanalysis Scientific Corp.

FAQ

What stock options were granted by Nanalysis Scientific Corp. on August 30, 2022?

On August 30, 2022, Nanalysis Scientific Corp. granted 377,500 stock options to employees, including 175,000 to an officer, at an exercise price of $1.10 per share.

What is the significance of the stock options granted by Nanalysis (NSCIF)?

The stock options are intended to align employee interests with those of shareholders and incentivize performance over the next three years as they vest.

What recent innovations has Nanalysis Scientific Corp. introduced?

Nanalysis has introduced a new 100MHz NMR device, which is the most powerful and advanced compact NMR device in the market.

How does Nanalysis enhance its market presence?

Nanalysis enhances its market presence through the strategic acquisition of K'Prime and by holding a 43% stake in Quad Systems AG.